Literature DB >> 20425467

Mantle cell lymphoma: Frontline and salvage therapy.

Jorge E Romaguera1.   

Abstract

Mantle cell lymphoma (MCL) is a therapeutic challenge because of its lower cure rate when compared with other lymphomas such as diffuse large cell lymphoma. The current emphasis in the treatment of newly diagnosed MCL has been on intensifying chemotherapy, but there is no consensus on the need to consolidate with autologous stem cell transplantation. These approaches, however, have not resulted in a cure. Newer strategies include the use of models to aid in tailoring therapy. Likewise, autologous stem cell consolidation does not cure relapsed disease. Because of its known graft-versus-lymphoma effect, allogeneic stem cell transplantation offers a potentially curative option for relapsed MCL. New insights into resistance pathways and new drugs created to inhibit them offer great promise in the treatment of newly diagnosed and previously treated MCL.

Entities:  

Mesh：

Year:  2008        PMID： 20425467     DOI： 10.1007/s11899-008-0029-3

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  34 in total

1.  Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma.

Authors:  J M Foran; A Z Rohatiner; B Coiffier; T Barbui; S A Johnson; W Hiddemann; J A Radford; A J Norton; S M Tollerfield; M P Wilson; T A Lister
Journal:  J Clin Oncol       Date:  1999-02       Impact factor: 44.544

2.  The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997.

Authors:  N L Harris; E S Jaffe; J Diebold; G Flandrin; H K Muller-Hermelink; J Vardiman; T A Lister; C D Bloomfield
Journal:  Histopathology       Date:  2000-01       Impact factor: 5.087

3.  Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

Authors:  Roswitha Forstpointner; Michael Unterhalt; Martin Dreyling; Hans-Peter Böck; Roland Repp; Hannes Wandt; Christiane Pott; John F Seymour; Bernd Metzner; Annette Hänel; Tanja Lehmann; Frank Hartmann; Hermann Einsele; Wolfgang Hiddemann
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

4.  Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.

Authors:  Christiane Pott; Carsten Schrader; Stefan Gesk; Lana Harder; Markus Tiemann; Thorsten Raff; Monika Brüggemann; Matthias Ritgen; Benedikt Gahn; Michael Unterhalt; Martin Dreyling; Wolfgang Hiddemann; Reiner Siebert; Peter Dreger; Michael Kneba
Journal:  Blood       Date:  2005-12-06       Impact factor: 22.113

5.  Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.

Authors:  B J Cohen; C Moskowitz; D Straus; A Noy; E Hedrick; A Zelenetz
Journal:  Leuk Lymphoma       Date:  2001 Sep-Oct

6.  Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).

Authors:  Georg Lenz; Martin Dreyling; Eva Hoster; Bernhard Wörmann; Ulrich Dührsen; Bernd Metzner; Hartmut Eimermacher; Andreas Neubauer; Hannes Wandt; Hjalmar Steinhauer; Sonja Martin; Else Heidemann; Ali Aldaoud; Reza Parwaresch; Joerg Hasford; Michael Unterhalt; Wolfgang Hiddemann
Journal:  J Clin Oncol       Date:  2005-01-24       Impact factor: 44.544

7.  Hematopoietic stem cell transplantation in mantle cell lymphoma.

Authors:  A K Ganti; P J Bierman; J C Lynch; R G Bociek; J M Vose; J O Armitage
Journal:  Ann Oncol       Date:  2005-02-07       Impact factor: 32.976

8.  Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

Authors:  Alessandro M Gianni; Michele Magni; Maurizio Martelli; Massimo Di Nicola; Carmelo Carlo-Stella; Silvana Pilotti; Alessandro Rambaldi; Sergio Cortelazzo; Caterina Patti; Guido Parvis; Fabio Benedetti; Saveria Capria; Paolo Corradini; Corrado Tarella; Tiziano Barbui
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

9.  Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma.

Authors:  José Rodríguez; Antonio Gutierrez; Andres Palacios; Mayda Navarrete; Isabel Blancas; Jesus Alarcón; María D Caballero; Silvia Fernández De Mattos; Jordi Gines; Jordi Martínez; Andres Lopez
Journal:  Leuk Lymphoma       Date:  2007-11

10.  Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.

Authors:  Olaf Determann; Eva Hoster; German Ott; Heinz Wolfram Bernd; Christoph Loddenkemper; Martin Leo Hansmann; Thomas E F Barth; Michael Unterhalt; Wolfgang Hiddemann; Martin Dreyling; Wolfram Klapper
Journal:  Blood       Date:  2007-12-12       Impact factor: 22.113
View more
  1 in total

1.  The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas.

Authors:  Pinelopi Argyriou; Panagiota Economopoulou; Sotirios Papageorgiou
Journal:  Adv Hematol       Date:  2011-06-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.